Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron ( (AU:BIT) ) just unveiled an update.
Biotron has completed the corporate and operational integration of Sedarex, consolidating ownership of SedRx, a next‑generation general anaesthetic that showed superior safety and cognitive outcomes in early human studies and has support for streamlined U.S. and European regulatory pathways. The company is preparing a submission to the European Medicines Agency for guidance on SedRx’s regulatory route and is also advancing work to explore additional neuroscientific indications, including sourcing drug product for upcoming animal studies.
In its antiviral portfolio, Biotron reported that its lead Hepatitis B candidate, BIT‑HBV001, significantly inhibited markers of Hepatitis Delta Virus in co‑infected cell models, reinforcing its potential role in future functional‑cure regimens for severe hepatitis. The company also strengthened its balance sheet with completion of a rights issue shortfall raising about A$878,000 before costs and refreshed its board by appointing Dr Graeme Wald as a non‑executive director following the retirement of Robert B. Thomas.
More about Biotron
Biotron Limited is an Australian biotechnology company focused on developing antiviral therapies and, through its acquisition of Sedarex Limited, a next‑generation general anaesthetic. Sedarex’s lead product SedRx targets the global anaesthesia market with a safer alfaxalone‑based formulation, while Biotron’s BIT‑HBV001 program is aimed at treating chronic Hepatitis B and related co‑infections.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.11M
For an in-depth examination of BIT stock, go to TipRanks’ Overview page.